Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Apr 19, 2024 11:54pm
236 Views
Post# 35999275

Weekend thoughts

Weekend thoughts

I ponder sometimes an old sales features & benefits vs cost psychology.

Applying some thinking to Onc:
We know they are working to get Pela to market. The Roche study being the most aggressive.

Who beinifits if Onc gets Pela to market?
Almost 1 million woman/ year being treated for cancer. Almost 1/2 million. Pancreatic cancer patients who will have a much better chance.
Roche employees will have minium a new product to work with. Increased jobs.
Roche will see increase sales & incresed profits.
ONC will need to further ramp up production. Securing jobs for onc employees.
ONC will eee sales & profits.
dritributors & health care professionals will have additional tolols in the fight for cancer.
Thr corporate value of both Onc & Roche would increase.
office leasing companies will feel better. More secure tenancy.
Business lawyers & auditors would see increased security dealing with ONC.
In simple terms many organizations & most importantly people will benifit from Getting Pelareorep to market.

Who benefits of Onc fails? 

the short sellers will make some short term gains. That is about it.

Two important words to blanket iver this philosophical journey.
karma & Dahrm


 

<< Previous
Bullboard Posts
Next >>